MG
TXG icon

Mather Group’s 10x Genomics TXG Stock Holding History

Mather Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed -$150 – 2185
2024
Q2 		$150 Buy
+4
New +$105 ﹤0.01% 2136
2021
Q3 		– Sell
-16,842
Closed -$3.3M – 305
2021
Q2 		$3.3M Sell
16,842
-4,002
-19% -$724K 0.08% 57
2021
Q1 		$3.77M Buy
20,844
+10,291
+98% +$1.78M 0.11% 53
2020
Q4 		$1.49M Sell
10,553
-17,313
-62% -$2.51M 0.05% 76
2020
Q3 		$3.47M Sell
27,866
-326
-1% -$34.2K 0.14% 49
2020
Q2 		$2.52M Sell
28,192
-6,506
-19% -$507K 0.12% 51
2020
Q1 		$2.16M Buy
+34,698
New +$2.71M 0.15% 48

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Mather Group's TXG Position: Q3 2024 in Review

Mather Group sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 4 shares — an estimated $150 sold.

Mather Group first reported a position in TXG in Q1 2020 and held it in 7 quarters. The position peaked at $3.77M in Q1 2021. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

  • Mather Group reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 4 10x Genomics shares in Q3 2024, an estimated $150.
  • Mather Group first reported a position in 10x Genomics in Q1 2020 and held it in 7 quarters.
  • Mather Group's 10x Genomics position peaked at $3.77M in Q1 2021.
  • 266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.